Parkinson's disease (PD) is a common neurodegenerative disorder characterized by
degeneration of the substantia nigra pars compacta and by accumulation of α-synuclein in …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Antisense oligonucleotides (ASOs) are promising therapeutics for treating various
neurological disorders. However, ASOs are unable to readily cross the mammalian blood …

Antisense oligonucleotides (ASOs) dosed into cerebrospinal fluid (CSF) distribute broadly
throughout the central nervous system (CNS). By modulating RNA, they hold the promise of …

Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …

Naturally occurring human genetic variants that are predicted to inactivate protein-coding
genes provide an in vivo model of human gene inactivation that complements knockout …

The genetic basis for most inherited neurodegenerative diseases has been identified, yet
there are limited disease-modifying therapies for these patients. A new class of drugs …

Parkinson's disease (PD) is a neurodegenerative disorder pathologically distinguished by
degeneration of dopaminergic neurons in the substantia nigra pars compacta. Muscle …

Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative
diseases. Atomic resolution of small molecule binding to such pathological protein …

Two recent, high‐profile manuscripts reported negative results with two parallel approaches
of passive immunization targeting α‐synuclein in a population of patients with early …